Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19
ConditionCOVID
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorTanta University
About this trial
ACEIs as treatment for COVID19
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients infected with covid 19
Disqualifiers
allergy or contraindications to the drug
Trial design
Design model
Parallel
Treatments tested in this trial
ACEIs
DrugCaptopril or enalapril
Conventional treatment
Drugalexoquine
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: ACEIsExperimental treatment 2 interventions
Group B: Conventional treatment of COVID19Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
number of patients with virological cure
number of patients with virological cure
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: